Our Journey

  1. Home
  2. »
  3. Our Journey

Our Journey: Pioneering the Future of Medicine

For decades, Anthem has been built on a simple, powerful belief: science can conquer the greatest health challenges.

This is the story of our journey, from our first breakthrough to the therapies of tomorrow.

It is a timeline defined by perseverance, patients and a relentless pursuit of progress.

in 2025

- Anthem Listed at BSE and NSE

- New expansion at Unit IV (30 acres) underway

- Expanded Unit II Custom Synthesis capacity to 376 KL

- Peptide, Hi Potent Manufacturing commissioned in Unit III

- Received 4th USFDA approval for Unit I

in 2024

- Successfully cleared 1st ANVISA audit for Unit I & II

- Successfully cleared 2nd USFDA audit for Unit II

- Expanded Unit II Fermentation capacity to 140 KL

- Commenced Chemistry Lab Operations at Unit III

in 2023

- Added Oligonucleotide lab in Unit I

- Successfully cleared 1st USFDA audit and 1st TGA audit for Unit II

in 2022

- Expanded Unit II Custom Synthesis capacity to 246 KL

- New Expansion at Unit III (NeoAnthem) underway

in 2021

- PE Investment by leading Indian PE Investor, True North

in 2019

- Successfully passed 3rd USFDA audit for Unit I

in 2018

- Commenced Operations at Unit II

in 2017

- Received 2nd USFDA approval for Unit I (2017)

in 2016

- Added High Potent Lab & Solid Phase Peptide Synthesis GMP Lab

in 2015

- Accreditations: IS0 9001:2008 & IS0 14001:2004

in 2014

- Accreditations: BS OHSAS 18001:2007 & AAALAC & GLP

in 2013

- Received 1st USFDA approval for Unit I

in 2011

- Received GMP authorization

in 2010

- Custom Synthesis Plant at Unit I Expanded (24 KL Capacity)

in 2009

- Received EUQP authorization

in 2008

- Discovery Biology Services

in 2007

- Started Operations at Unit I Chemistry Services

in 2006

- Company incorporated